Theriva Biologics FY2025 cash $13.1M; licensing deal, EMA guidance on VCN-01 Phase 3

Theriva Biologics, Inc.

G&A expense rose 109% to $15.4M on $9.0M contingent consideration from VCN-01 trial success.
R&D expense fell 28% to $8.6M as VIRAGE Phase 2b completed; lower trial costs offset by patent spending.
Cash $13.1M at Dec 31, 2025; $15.2M at Feb 26, 2026 providing runway into Q1 2027.
Licensed SYN-020 to Rasayana for up to $38M milestones plus royalties; received $300K upfront.
EMA agreed on Phase 3 trial design for VCN-01 in PDAC; End-of-Phase 2 FDA meeting planned 1H 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theriva Biologics, Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

Rockville, MD, March 12, 2026 – TherivaTM Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-026765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.